AstraZeneca & Ionis’ phase III trial for Wainua in patients with transthyretin-mediated amyloid cardiomyopathy fails to meet primary efficacy endpoint: Cambridge, UK Friday, Jul ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results